Understanding Late Responses to Anti-CGRP Migraine Therapy

Research Summary

A recent review published in "Pain Management" highlights intriguing findings regarding the timing of responses to anti-CGRP therapies for migraines. While traditional migraine preventatives often fall short, monoclonal antibodies targeting the calcitonin gene-related peptide (CGRP) show promise, typically reducing migraine frequency by 50% within three months. However, real-world studies reveal that some patients, referred to as "late" and "ultra-late responders," require longer treatment durations of six to twelve months to experience significant benefits. Approximately one-third of initial non-responders improve by six months, and more see results by twelve months. This emphasizes the importance of patience and extended treatment to maximize therapeutic outcomes, urging consideration of prolonged therapy durations for those on anti-CGRP regimens.

Study Details

📄 Title: Late response to anti-CGRP therapy for migraine.

👥 Research Team: Marsico O, Lioi M, Trimboli M

📚 Published In: Pain Manag

📅 Publication Date: 2025 Aug 21

🔗 Read Study

⚕️ Medical Disclaimer: This summary is generated automatically from recent migraine research. Always consult with healthcare professionals for medical advice.